 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...51525354555657585960616263» |
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial initiation date, Trial primary completion date, Adverse events: Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (clinicaltrials.gov) - Aug 9, 2018
P=N/A, N=400, Not yet recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Trial primary completion date: Feb 2018 --> Oct 2018 | Initiation date: Feb 2018 --> Oct 2018
- | Trial primary completion date: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Aug 7, 2018
P2, N=84, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Feb 2018 --> Oct 2018 | Initiation date: Feb 2018 --> Oct 2018 Trial primary completion date: Jul 2018 --> Jan 2019
- | Selzentry (maraviroc) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) (clinicaltrials.gov) - Aug 7, 2018
P4, N=186, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jul 2018 --> Jan 2019 Trial primary completion date: Oct 2018 --> Oct 2019
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Metastases: Immune Recovery in Advanced , ARV-na (clinicaltrials.gov) - Aug 3, 2018
P4, N=104, Active, not recruiting, Sponsor: Juan A. Arnaiz
Trial primary completion date: Oct 2018 --> Oct 2019 Recruiting --> Active, not recruiting
- || Selzentry (maraviroc) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure (clinicaltrials.gov) - Aug 2, 2018
P=N/A, N=30, Active, not recruiting, Sponsor: Federal University of S
Recruiting --> Active, not recruiting Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2018 --> Mar 2019
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial initiation date: Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (clinicaltrials.gov) - Aug 1, 2018
P4, N=20, Recruiting, Sponsor: Fundacion Clinic per a la Recerca Biom
Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2018 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Apr 2018
- | Tivicay (dolutegravir) / ViiV Healthcare
New P2 trial: Evaluation of Third-line cART Regimen in Cambodia (3DICAM) (clinicaltrials.gov) - Jul 26, 2018
P2, N=54, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- | Enrollment closed: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Jul 26, 2018
P2, N=84, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Apr 2018 Recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change: IMPAACT P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents (clinicaltrials.gov) - Jul 24, 2018
P1/2, N=300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting N=160 --> 300
- ||| Tivicay (dolutegravir) / ViiV Healthcare
New trial: Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women (clinicaltrials.gov) - Jul 15, 2018
P=N/A, N=250, Active, not recruiting, Sponsor: ViiV Healthcare
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
New P2 trial: Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (clinicaltrials.gov) - Jul 15, 2018
P2, N=120, Not yet recruiting, Sponsor: Philip Grant
- || Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women (clinicaltrials.gov) - Jul 12, 2018
P=N/A, N=250, Active, not recruiting, Sponsor: ViiV Healthcare
N=160 --> 300 Not yet recruiting --> Active, not recruiting
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change, Trial completion date, Trial primary completion date: D (clinicaltrials.gov) - Jul 10, 2018
P3b/4, N=1010, Recruiting, Sponsor: Kirby Institute
Not yet recruiting --> Active, not recruiting N=610 --> 1010 | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2019 --> Dec 2020
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: NAMSAL: Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings (clinicaltrials.gov) - Jul 3, 2018
P3, N=616, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
N=610 --> 1010 | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2019 --> Dec 2020 Recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Enrollment change, Trial completion date: DOLBI: Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression (clinicaltrials.gov) - Jul 2, 2018
P=N/A, N=155, Completed, Sponsor: Asociacion para el Estudio de las Enfermedades Infecciosas
Recruiting --> Active, not recruiting Recruiting --> Completed | N=100 --> 155 | Trial completion date: Mar 2018 --> Jun 2018
- |||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (clinicaltrials.gov) - Jun 19, 2018
P3, N=240, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed | N=100 --> 155 | Trial completion date: Mar 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- |||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (clinicaltrials.gov) - Jun 5, 2018
P3, N=240, Not yet recruiting, Sponsor: Gilead Sciences
- | Tivicay (dolutegravir) / ViiV Healthcare
New P2 trial: Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept. (clinicaltrials.gov) - Jun 3, 2018
P2, N=36, Recruiting, Sponsor: Instituto de Investigaci
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: IMPAACT P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents (clinicaltrials.gov) - Jun 2, 2018
P1/2, N=160, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> Jun 2020
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
New P2 trial: Rapid HIV Treatment Initiation, Access and Engagement in Care (clinicaltrials.gov) - Apr 30, 2018
P2, N=20, Recruiting, Sponsor: Johns Hopkins University
- Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=20, Active, not recruiting, Sponsor: Southern Illinois Healthcare Foundation
Trial primary completion date: May 2018 --> Jun 2020 Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: Dec 2017 --> Apr 2018
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date, Metastases: Immune Recovery in Advanced , ARV-na (clinicaltrials.gov) - Apr 13, 2018
P4, N=108, Recruiting, Sponsor: Juan A. Arnaiz
Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: Dec 2017 --> Apr 2018 Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) (clinicaltrials.gov) - Apr 9, 2018
P3, N=100, Recruiting, Sponsor: Ospedale San Raffaele
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG) (clinicaltrials.gov) - Apr 9, 2018
P4, N=415, Completed, Sponsor: St Stephens Aids Trust
Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019 Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change: Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers (clinicaltrials.gov) - Mar 30, 2018
P1, N=50, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed N=30 --> 50
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Head-to-Head, IO biomarker: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment na (clinicaltrials.gov) - Mar 12, 2018
P3, N=700, Active, not recruiting, Sponsor: ViiV Healthcare
N=30 --> 50 Trial completion date: Feb 2024 --> Mar 2020
- || Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: DGVTAF: Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection (clinicaltrials.gov) - Mar 7, 2018
P4, N=74, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Feb 2024 --> Mar 2020 Trial completion date: Jan 2020 --> Apr 2020 | Trial primary completion date: Jan 2020 --> Apr 2020
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial initiation date, Trial primary completion date, Adverse events: Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (clinicaltrials.gov) - Feb 14, 2018
P=N/A, N=400, Not yet recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Trial completion date: Jan 2020 --> Apr 2020 | Trial primary completion date: Jan 2020 --> Apr 2020 Initiation date: Sep 2016 --> Feb 2018 | Trial primary completion date: Mar 2017 --> Feb 2018
- |||| Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection (clinicaltrials.gov) - Jan 25, 2018
P3, N=113, Active, not recruiting, Sponsor: ViiV Healthcare
Initiation date: Sep 2016 --> Feb 2018 | Trial primary completion date: Mar 2017 --> Feb 2018 Trial primary completion date: Dec 2017 --> Sep 2017
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial initiation date: DolPHIN-2: Dolutegravir in Pregnant HIV Mothers and Their Neonates (clinicaltrials.gov) - Jan 25, 2018
P3, N=250, Recruiting, Sponsor: University of Liverpool
Trial primary completion date: Dec 2017 --> Sep 2017 Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Jan 2018
- | Selzentry (maraviroc) / ViiV Healthcare
Trial primary completion date, Combination therapy: Switch to Maraviroc + Integrase Inhibitor (clinicaltrials.gov) - Jan 23, 2018
P3, N=30, Recruiting, Sponsor: University of Maryland
Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Jan 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Trial primary completion date: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jan 4, 2018
P1, N=20, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- ||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed, Trial primary completion date: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed (clinicaltrials.gov) - Dec 21, 2017
P3, N=567, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Nov 2018
- | Tivicay (dolutegravir) / ViiV Healthcare
New trial: Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=270, Recruiting, Sponsor: Columbia University
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Enrollment change: Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana (clinicaltrials.gov) - Dec 18, 2017
P=N/A, N=270, Recruiting, Sponsor: Columbia University
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Nov 2018 Not yet recruiting --> Recruiting | N=60 --> 270 | Not yet recruiting --> Recruiting | N=60 --> 270 | Not yet recruiting --> Recruiting | N=60 --> 270
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (clinicaltrials.gov) - Dec 4, 2017
P4, N=20, Not yet recruiting, Sponsor: Fundacion Clinic per a la Recerca Biom
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: DIORR: Dolutegravir Impact on Residual Replication (clinicaltrials.gov) - Nov 20, 2017
P4, N=40, Completed, Sponsor: University of Melbourne
Not yet recruiting --> Recruiting | N=60 --> 270 | Not yet recruiting --> Recruiting | N=60 --> 270 | Not yet recruiting --> Recruiting | N=60 --> 270 Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: DOLBI: Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=100, Recruiting, Sponsor: Asociacion para el Estudio de las Enfermedades Infecciosas
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Mar 2018
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: ODYSSEY: A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART (clinicaltrials.gov) - Nov 8, 2017
P2/3, N=700, Recruiting, Sponsor: PENTA Foundation
Trial primary completion date: Mar 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- Selzentry (maraviroc) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=30, Active, not recruiting, Sponsor: Federal University of S
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2017 --> Mar 2018
- | Tivicay (dolutegravir) / ViiV Healthcare
Clinical: Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=60, Not yet recruiting, Sponsor: Columbia University
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Monotherapy: MONODO: A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients (clinicaltrials.gov) - Nov 1, 2017
P2, N=8, Completed, Sponsor: Calmy Alexandra
Trial primary completion date: Jan 2017 --> Mar 2018 Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: Phase 4 Study of Dolutegravir (DTG) in Russian Federation (clinicaltrials.gov) - Nov 1, 2017
P4, N=34, Recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Trial primary completion date: SSAT073: The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers (clinicaltrials.gov) - Oct 31, 2017
P1, N=20, Active, not recruiting, Sponsor: St Stephens Aids Trust
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Apr 2018
- Tivicay (dolutegravir) / ViiV Healthcare
New trial: PRJ2203: Dolutegravir Post Authorization Safety Study (PASS) (clinicaltrials.gov) - Oct 31, 2017
P=N/A, N=1, Active, not recruiting, Sponsor: ViiV Healthcare
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change, Trial primary completion date: DGVTAF: Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection (clinicaltrials.gov) - Oct 26, 2017
P4, N=74, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Apr 2018 N=24 --> 74 | Trial primary completion date: Jan 2018 --> Jan 2020
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: DOL-ART: A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=411, Completed, Sponsor: ViiV Healthcare
N=24 --> 74 | Trial primary completion date: Jan 2018 --> Jan 2020 Active, not recruiting --> Completed
- | Prezcobix (darunavir/cobicistat) / Gilead, J&J, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial initiation date: OPTIPRIM-2: National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection (clinicaltrials.gov) - Oct 25, 2017
P3, N=100, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Apr 2017
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Phase 4 Study of Dolutegravir (DTG) in Russian Federation (clinicaltrials.gov) - Oct 23, 2017
P4, N=34, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Apr 2017 Recruiting --> Active, not recruiting
- |||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: D (clinicaltrials.gov) - Oct 20, 2017
P3b/4, N=610, Recruiting, Sponsor: Kirby Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting